ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¿¹Ãø ¹× ºÐ¼®(-2028³â) : Áö¿ªº°, Á¦Ç°º°, ÀýÂ÷º°, ÃÖÁ¾ »ç¿ëÀÚº°
North America Structural Heart Market Forecast to 2028 - Regional Analysis - by Product, Procedure, and End User
»óǰÄÚµå : 1394004
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 133 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,937,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,368,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,800,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå(Structural Heart) ½ÃÀåÀº 2022³â 69¾ï 6,750¸¸ ´Þ·¯¿¡¼­ 2028³â 112¾ï 147¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2028³â±îÁöÀÇ CAGRÀº 8.2%·Î ÃßÁ¤µË´Ï´Ù.

Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼­ºñ½ºÀÇ °¡¿ë¼ºÀº ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀ» µÞ¹Þħ

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°è »ç¸Á ¿øÀÎ 2À§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÉÇ÷°ü ÁúȯÀ» °ü¸®Çϱâ À§ÇØ ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ½ÉÀå ÆÇ¸· ÁúȯÀº ½ÉºÎÀüÀÇ °¡Àå ÈçÇÑ ¿øÀÎ Áß Çϳª·Î ¿¹»óµË´Ï´Ù. ´ëµ¿¸Æ ÆÇ¸·°ú ½Â¸ðÆÇ¸·ÀÇ ÅðÇ༺ Áúȯ, »ï÷ÆÇ¸· ±â´É Àå¾Ö ÁúȯÀº ½ÉÇÑ °æ¿ì ÀÓ»ó °æ°ú¸¦ ¾ÇÈ­½Ãŵ´Ï´Ù. ÃÖ±Ù ±¸Á¶Àû ½ÉÀå Áúȯ¿¡ ´ëÇÑ ÃÖ¼Ò Ä§½ÀÀû, ¿Ü°úÀû, Ä«Å×ÅÍ ±â¹Ý ÁßÀç¼úÀÌ ±Þ°ÝÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±¸Á¶Àû ½ÉÀåÀº ½ÉÀå ÆÇ¸· ¼ö¼ú°ú °æÇÇÀû Ä«Å×ÅÍ ½Ã¼ú·Î ±¸¼ºµÈ ÁøÈ­ÇÏ´Â ºÐ¾ß·Î, ½ÉÀå¿Ü°ú Àü¹®ÀÇ¿Í ³»°ú Àǻ縦 À§ÇÑ ´Ù¾çÇÑ ±³À° ÇÁ·Î±×·¥ÀÌ ¸¶·ÃµÇ°í ÀÖ½À´Ï´Ù. Áö³­ 10³â µ¿¾È ±¸Á¶Àû ½ÉÀå ÁúȯÀÇ ¹ßº´·üÀÌ ±ÞÁõÇÔ¿¡ µû¶ó ÀηÂÀÇ ÀûÀýÇÑ ¿ª·®À» È®º¸Çϱâ À§ÇÑ °ø½ÄÀûÀÎ ±³À° ÇÁ·Î±×·¥ÀÇ °³¹ßÀÌ ÇÊ¿äÇØÁ³½À´Ï´Ù. ±³À°ÀÇ ±¸Á¶, ±â°£, ¹üÀ§´Â ÇÁ·Î±×·¥¸¶´Ù Å©°Ô ´Ù¸¨´Ï´Ù. ´ëºÎºÐÀÇ ÇÁ·Î±×·¥Àº °æÇÇÀû ´ëµ¿¸ÆÆÇ¸· ġȯ¼ú(TAVR)¿¡ ´ëÇÑ È®½ÇÇÑ ³ëÃâÀ» Á¦°øÇÏ´Â µ¿½Ã¿¡ ½É¹æÁß°Ý ¶Ç´Â ½É½ÇÁß°Ý °á¼Õ Æó¼â¼ú, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â¼ú, ¼±Ãµ¼º ½ÉÀå °á¼Õ ÁßÀç¼ú¿¡ ´ëÇÑ ´ú ´Ù¾çÇÏ°í ´Ù¾çÇÑ °æÇèÀ» Á¦°øÇÕ´Ï´Ù. °æÇÇÀû ½Â¸ðÆÇ¸· ġȯ¼ú(TAVR), MitraClip ½Â¸ðÆÇ¸· ¼ö¸® ½Ã½ºÅÛ(Abbott Vascular), ÁÂ½É¹æ ºÎ¼Ó±â Æó»ö¼ú(LAAO) ½Ã¼úÀÇ µîÀåÀ¸·Î º¹ÀâÇÑ ½ÉÇ÷°ü ÁúȯÀ» °¡Áø ȯÀÚ¸¦ Ä¡·áÇϱâ À§ÇØ ½ÃÇàµÇ´Â ±¸Á¶Àû ½ÉÀå ½Ã¼úÀÇ ¾çÀÌ Å©°Ô Áõ°¡Çß½À´Ï´Ù. ¸¹Àº ±â°ü¿¡¼­ À¯ÀԵǴ ȯÀÚ¸¦ ¼ö¿ëÇϱâ À§ÇØ ±¸Á¶Àû ½ÉÀå ÇÁ·Î±×·¥À» À§ÇÑ Ã¼°èÀûÀÎ Çü½ÄÀÇ ¼­ºñ½º ¹× ½Ã¼úÀ» °³¹ßÇß½À´Ï´Ù. SHD ¼ö·ÃÀº Àü¹ÝÀûÀ¸·Î Èï¹Ì·Ó°í µµÀüÀûÀÌ¸ç º¸¶÷ ÀÖ´Â °úÁ¤ÀÔ´Ï´Ù. ÀÌ ºÐ¾ß°¡ ¹ßÀüÇÔ¿¡ µû¶ó ÃÖ°íÀÇ È¯ÀÚ Ä¡·á ǰÁúÀ» º¸ÀåÇϱâ À§ÇØ SHD ±³À°ÀÇ Ç¥ÁØÈ­°¡ ¸Å¿ì Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¾Õ¼­ ¼³¸íÇÑ ¼ö¸¹Àº °í·Á »çÇ×À» Ž»öÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ´Â ¸àÅ並 ã´Â °ÍÀº ±³À°¿¡¼­ ½Ç¹«·Î ¼º°øÀûÀ¸·Î ÀüȯÇÏ´Â µ¥ °¡Àå Å« ÀÚ»êÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº 2022³âºÎÅÍ 2028³â±îÁö CAGR 8.2%·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº Çõ½ÅÀûÀÎ ±¸Á¶Àû ½ÉÀå ¼­ºñ½º, ½ÉÇ÷°ü Áúȯ ¼ö ¹× ÈÆ·Ã ÇÁ·Î±×·¥ Áõ°¡ÀÔ´Ï´Ù. ±×·¯³ª ±¸Á¶Àû ½ÉÀå Àåºñ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦°¡ °è¼ÓµÇ´Â Ä¡·áÀÇ ³ôÀº ºñ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù.

2028³â±îÁö ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀÇ ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Á¦Ç°, ÀýÂ÷, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

Á¦Ç°º°·Î ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº Æó»ö±â, ȯÇü ¼ºÇü ¸µ, ½ÉÀå ÆÇ¸· dz¼± µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ Æó»ö±â ºÎ¹®Àº °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÀýÂ÷º°·Î º¸¸é ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº ½ÉÀå ÆÇ¸· ÇùÂøÁõ, ½ÉÀå ÆÇ¸· ¿ª·ùÁõ, ÁÂ½É¹æ ºÎ¼Ó±â Æó¼â ºÎÀüÁõÀ¸·Î ±¸ºÐµË´Ï´Ù. ½ÉÀå ÆÇ¸· ÇùÂøÁõ ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î º¸¸é ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, Micro Interventional Devices Inc´Â ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå- ÁÖ¿ä Æ÷ÀÎÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-½ÃÀå »óȲ

Á¦5Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦6Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå-ºÏ¹Ì ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : Á¦Ç°º°

Á¦8Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÀýÂ÷º°

Á¦9Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ±¹°¡º° ºÐ¼®

Á¦11Àå ºÏ¹ÌÀÇ ±¸Á¶Àû ½ÉÀå ½ÃÀå : »ê¾÷ Á¤¼¼

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The North America structural heart market is expected to grow from US$ 6,967.50 million in 2022 to US$ 11,201.47 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2022 to 2028.

Availability of Innovative Structural Heart Services Fuel North America Structural Heart Market

According to the World Health Organization (WHO), cardiovascular diseases are the second leading cause of death worldwide. Therefore, various initiatives are being taken to control cardiovascular diseases. Heart valve disease is expected to be one of the most common causes of heart failure. Degenerative diseases of aortic and mitral valves, and diseases of dysfunctional tricuspid valves lead to a worse clinical course in severe cases. Minimally invasive, surgical, and catheter-based interventions for structural heart disease have increased dramatically recently. The structural heart is an evolving field consisting of heart valve surgeries and transcatheter procedures; therefore, various training programs are being arranged for cardiac surgeons and physicians. Over the past decade, the burgeoning incidence of structural heart disease has necessitated the development of formal training programs to ensure the appropriate competency of workforces. The structure, length, and scope of training vary greatly between programs. Most programs provide solid exposure on transcatheter aortic valve replacement (TAVR) procedures, simultaneously providing a lesser and variable experience of atrial septal or ventricular septal defect closure, left atrial appendage closure, and congenital heart defect interventions. With the advent of TAVR, the MitraClip mitral valve repair system (Abbott Vascular), and left atrial appendage occlusion (LAAO) procedures, there has been a significant increase in the volume of structural cardiac procedures performed for treating patients with complex cardiovascular conditions. Many organizations have developed services and procedural offerings in an organized format for the structural cardiac program to accommodate the influx of patients. Training in SHD is exciting, challenging, and rewarding overall. As the field evolves, standardization of SHD training becomes extremely important to ensure the best quality of patient care. Finding a mentor to help navigate the numerous considerations outlined can be the best asset to successfully transitioning from training to practice.

North America Structural Heart Market Overview

The North America Structural heart market is estimated to grow at a CAGR of 8.2% from 2022 to 2028. Key factors driving the market growth are innovative structural heart services and rise in the number of cardiovascular diseases and training programs. However, high cost of procedure followed by stringent regulations regarding structure heart device are the major factor hampering the growth of the market.

North America Structural Heart Market Revenue and Forecast to 2028 (US$ Million)

North America Structural Heart Market Segmentation

The North America structural heart market is segmented into product, procedure, end user, and country.

Based on product, the North America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the North America structural heart market in 2022.

Based on procedure, the North America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the North America structural heart market in 2022.

Based on end user, the North America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share of the North America structural heart market in 2022.

Based on country, the North America structural heart market is segmented into US, Canada, and Mexico. US dominated the North America structural heart market in 2022.

Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, and Micro Interventional Devices Inc are some of the leading companies operating in the North America structural heart market.

Reasons to Buy:

Table Of Contents

1. Introduction

2. North America Structural Heart Market - Key Takeaways

3. Research Methodology

4. North America Structural Heart Market - Market Landscape

5. North America Structural Heart Market - Key Market Dynamics

6. North America Structural Heart Market -North America Analysis

7. North America Structural Heart Market - Revenue and Forecast to 2028 - by Product

8. North America Structural Heart Market - Revenue and Forecast to 2028 - by Procedure

9. North America Structural Heart Market - Revenue and Forecast to 2028 - by End User

10. North America Structural Heart Market - Revenue and Forecast to 2028 -Country Analysis

11. North America Structural Heart Market -Industry Landscape

12. Company Profiles

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â